Portal de Periódicos da CAPES

Percentage of Positive Biopsy Cores as Predictor of Clinical Outcome in Prostate Cancer Treated With Radiotherapy.

2002; Lippincott Williams & Wilkins; Volume: 168; Issue: 5 Linguagem: Inglês

10.1016/s0022-5347(05)64280-2

1527-3792

Larry L. Kestin, Neal S. Goldstein, Frank A. Vicini, Alvaro A. Martinez,

Bladder and Urothelial Cancer Treatments

No AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 Nov 2002Percentage of Positive Biopsy Cores as Predictor of Clinical Outcome in Prostate Cancer Treated With Radiotherapy. LARRY L. KESTIN, NEAL S. GOLDSTEIN, FRANK A. VICINI, and ALVARO A. MARTINEZ LARRY L. KESTINLARRY L. KESTIN , NEAL S. GOLDSTEINNEAL S. GOLDSTEIN , FRANK A. VICINIFRANK A. VICINI , and ALVARO A. MARTINEZALVARO A. MARTINEZ View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)64280-2AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: The clinical significance of pretreatment biopsy characteristics is not well understood relative to known prognostic factors. We performed a complete pathology analysis of pretreatment biopsy specimens in an attempt to clarify their impact on clinical outcome following radiotherapy. Materials and Methods: From 1991 to 1999, 160 patients with locally advanced prostate cancer were prospectively treated with external beam radiotherapy in combination with high dose rate brachytherapy at our hospital and had pretreatment biopsy material available for complete pathological review. Patients with pretreatment prostate specific antigen (PSA) 10.0 ng./ml. or greater, Gleason 7 or greater or clinical stage T2b-T3c N0 M0 disease were eligible for study entry. Pelvic external beam radiotherapy (46.0 Gy.) was supplemented with 3 (1991 to 1995) or 2 (1995 to 1999) ultrasound guided transperineal interstitial 192iridium high dose rate implants. The brachytherapy dose was escalated from 5.50 to 10.50 Gy. per implant. All pretreatment biopsy specimen slides from each case were reviewed by a single pathologist (N. S. G.). Median followup was 4.2 years. Biochemical failure was defined as 3 consecutive PSA increases. Results: On univariate analysis pretreatment PSA, Gleason score, clinical T classification, percentage of positive biopsy cores, dose per implant and total radiotherapy dose (equivalent in 2 Gy. fractions) were significantly associated with biochemical failure. Perineural invasion was of borderline significance (p = 0.07). On univariate analysis for clinical failure only Gleason score and percent positive cores were significant. Percent positive cores was associated with biochemical and clinical failure whether analyzed in subgroups or as a continuous variable. Patients with less than 33% positive cores had a 5-year biochemical control rate of 83% and 5-year clinical failure rate of only 7%. Conversely, patients with more than 67% positive cores had a 5-year biochemical control rate of only 57% and 25% had clinical failure at 5 years. Since percent positive cores correlated with biochemical and clinical failure, an analysis was performed to determine which other prognostic factors were associated with percent positive cores. Pretreatment PSA level, Gleason score, clinical T classification and perineural invasion were significantly associated with a higher percent positive cores. Nevertheless, on Cox multiple regression analysis higher percent positive cores, pretreatment PSA and Gleason score remained independently associated with biochemical failure but not T classification. On Cox multiple regression analysis for clinical failure only Gleason score remained independently significant with percent positive cores maintaining borderline significance (p = 0.07). Conclusions: Percent positive pretreatment biopsy cores is a powerful predictor of biochemical and clinical outcome for prostate cancer treated with radiotherapy, independent of other known prognostic factors. Percent positive cores should be seriously considered as a primary factor in risk group stratification for prostate cancer. References 1 : Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: intermediate-term results. J Urol1998; 160: 2428. Link, Google Scholar 2 : Long-term results of radical retropubic prostatectomy in men with high grade carcinoma of the prostate. J Urol1997; 158: 1460. Link, Google Scholar 3 : Combined-modality staging for localized adenocarcinoma of the prostate. Oncology2001; 15: 1049. Medline, Google Scholar 4 : The role of perineural invasion and other biopsy characteristics as prognostic markers for localized prostate cancer. Semin Urol Oncol1998; 16: 124. Medline, Google Scholar 5 : Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol2000; 18: 1164. Crossref, Medline, Google Scholar 6 : The clinical utility of the percent of positive prostate biopsies in predicting biochemical outcome following external-beam radiation therapy for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys2001; 49: 679. Crossref, Medline, Google Scholar 7 : Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleason score. J Urol2002; 167: 516. Link, Google Scholar 8 : Positive fraction of systematic biopsies predicts risk of relapse after radical prostatectomy. Urology1998; 52: 1079. Crossref, Medline, Google Scholar 9 American Joint Committee on Cancer: Prostate. In: AJCC Cancer Staging Manual. Edited by . Philadelphia: Lippincott-Raven1992: 181. chapt. 31. Google Scholar 10 : Matched-pair analysis of conformal high-dose-rate brachytherapy boost versus external-beam radiation therapy alone for locally advanced prostate cancer. J Clin Oncol2000; 18: 2869. Crossref, Medline, Google Scholar 11 : Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: the William Beaumont phase II dose-escalating trial. Int J Radiat Oncol Biol Phys2000; 47: 343. Crossref, Medline, Google Scholar 12 : Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys2002; 52: 6. Crossref, Medline, Google Scholar 13 : Defining biochemical cure for prostate carcinoma patients treated with external beam radiation therapy. Cancer1999; 86: 1557. Crossref, Medline, Google Scholar 14 : A comparison of external beam radiation therapy versus radical prostatectomy for patients with low risk prostate carcinoma diagnosed, staged, and treated at a single institution. Cancer2000; 88: 425. Crossref, Medline, Google Scholar 15 : The correlation of serial prostate specific antigen measurements with clinical outcome after external beam radiation therapy of patients for prostate carcinoma. Cancer2000; 88: 2305. Crossref, Medline, Google Scholar 16 : Staging prostate cancer—1997: current methods and limitations. Eur Urol1997; 32: 2. Medline, Google Scholar 17 : The role of transrectal ultrasound-guided biopsy-based staging, preoperative serum prostate-specific antigen, and biopsy Gleason score in prediction of final pathologic diagnosis in prostate cancer. Urology1995; 46: 205. Crossref, Medline, Google Scholar 18 : Patients with abnormal ultrasound of the prostate but normal digital rectal examination should be classified as having clinical stage T2 tumors. J Urol2000; 163: 1486. Link, Google Scholar 19 : Sextant prostate biopsies. A histopathologic correlation with radical prostatectomy specimens. Cancer1995; 75: 530. Crossref, Medline, Google Scholar 20 : Predicting prostate carcinoma volume and stage at radical prostatectomy by assessing needle biopsy specimens for percent surface area and cores positive for carcinoma, perineural invasion, Gleason score, DNA ploidy and proliferation, and preoperative serum prostate specific antigen: a report of 454 cases. Cancer2001; 91: 2196. Crossref, Medline, Google Scholar 21 : Prediction of capsular perforation and seminal vesicle invasion in prostate cancer. J Urol1996; 155: 1361. Link, Google Scholar 22 : Systematic biopsies accurately predict extracapsular extension of prostate cancer and persistent/recurrent detectable PSA after radical prostatectomy. Urology1994; 44: 371. Crossref, Medline, Google Scholar 23 : Analysis of risk factors associated with prostate cancer extension to the surgical margin and pelvic node metastasis at radical prostatectomy. J Urol1993; 150: 1845. Link, Google Scholar 24 : Clinical and pathologic tumor characteristics of prostate cancer as a function of the number of biopsy cores: a retrospective study. Urology1998; 52: 808. Crossref, Medline, Google Scholar 25 : A prospective randomized trial comparing 6 versus 12 prostate biopsy cores: impact on cancer detection. J Urol2000; 164: 388. Link, Google Scholar From the Departments of Radiation Oncology and Anatomic Pathology, William Beaumont Hospital, Royal Oak, Michigan© 2002 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited by Sivaraman A and Barret E (2017) Reply to Runqiang Yuan and Hongxing Huang's Letter to the Editor re: Ernesto R. Cordeiro Feijoo, Arjun Sivaraman, Eric Barret, et al. Focal High-intensity Focused Ultrasound Targeted Hemiablation for Unilateral Prostate Cancer: A Prospective Evaluation of Oncologic and Functional Outcomes. Eur Urol 2016;69:214–20European Urology, 10.1016/j.eururo.2017.01.034, VOL. 71, NO. 5, (e148-e149), Online publication date: 1-May-2017. Hall W, Lawton C, Jani A, Pollack A and Feng F (2017) Biomarkers of Outcome in Patients With Localized Prostate Cancer Treated With RadiotherapySeminars in Radiation Oncology, 10.1016/j.semradonc.2016.09.001, VOL. 27, NO. 1, (11-20), Online publication date: 1-Jan-2017. Yorozu A, Kuroiwa N, Takahashi A, Toya K, Saito S, Nishiyama T, Yagi Y, Tanaka T, Shiraishi Y and Ohashi T (2015) Permanent prostate brachytherapy with or without supplemental external beam radiotherapy as practiced in Japan: Outcomes of 1300 patientsBrachytherapy, 10.1016/j.brachy.2014.06.008, VOL. 14, NO. 2, (111-117), Online publication date: 1-Mar-2015. Ohashi T, Yorozu A, Saito S, Momma T, Nishiyama T, Yamashita S, Shiraishi Y and Shigematsu N (2014) Combined brachytherapy and external beam radiotherapy without adjuvant androgen deprivation therapy for high-risk prostate cancerRadiation Oncology, 10.1186/1748-717X-9-13, VOL. 9, NO. 1, Online publication date: 1-Dec-2014. Phillips J, Chen M, Zhang D, Loffredo M, Kantoff P and D’Amico A (2014) Percent positive biopsy cores and the risk of death from prostate cancer in men with unfavorable-risk prostate cancerJournal of Radiation Oncology, 10.1007/s13566-014-0158-3, VOL. 3, NO. 3, (307-312), Online publication date: 1-Sep-2014. Ward J and Pisters L (2013) Considerations for patient selection for focal therapyTherapeutic Advances in Urology, 10.1177/1756287213496127, VOL. 5, NO. 6, (330-337), Online publication date: 1-Dec-2013. Edwards H, Oakley F, Koyama T and Hameed O (2013) The Impact of Tumor Size in Breast Needle Biopsy Material on Final Pathologic Size and Tumor StageAmerican Journal of Surgical Pathology, 10.1097/PAS.0b013e31828c63d0, VOL. 37, NO. 5, (739-744), Online publication date: 1-May-2013. Muto S and Horie S (2013) High Intensity Focused Ultrasound Imaging and Focal Therapy of Early Prostate Cancer, 10.1007/978-1-62703-182-0_20, (273-282), . Bian S, Kuban D, Levy L, Oh J, Castle K, Pugh T, Choi S, McGuire S, Nguyen Q, Frank S, Nguyen P, Lee A and Hoffman K (2012) Addition of short-term androgen deprivation therapy to dose-escalated radiation therapy improves failure-free survival for select men with intermediate-risk prostate cancerAnnals of Oncology, 10.1093/annonc/mds001, VOL. 23, NO. 9, (2346-2352), Online publication date: 1-Sep-2012. Huang J, Vicini F, Williams S, Ye H, McGrath S, Ghilezan M, Krauss D, Martinez A and Kestin L (2012) Percentage of Positive Biopsy Cores: A Better Risk Stratification Model for Prostate Cancer?International Journal of Radiation Oncology*Biology*Physics, 10.1016/j.ijrobp.2011.09.043, VOL. 83, NO. 4, (1141-1148), Online publication date: 1-Jul-2012. Buyyounouski M, Pickles T, Kestin L, Allison R and Williams S (2012) Validating the Interval to Biochemical Failure for the Identification of Potentially Lethal Prostate CancerJournal of Clinical Oncology, 10.1200/JCO.2011.35.1924, VOL. 30, NO. 15, (1857-1863), Online publication date: 20-May-2012. Qian Y, Feng F, Halverson S, Blas K, Sandler H and Hamstra D (2011) The Percent of Positive Biopsy Cores Improves Prediction of Prostate Cancer–Specific Death in Patients Treated With Dose-Escalated RadiotherapyInternational Journal of Radiation Oncology*Biology*Physics, 10.1016/j.ijrobp.2011.01.007, VOL. 81, NO. 3, (e135-e142), Online publication date: 1-Nov-2011. Hayden A, Martin J, Kneebone A, Lehman M, Wiltshire K, Skala M, Christie D, Vial P, McDowall R and Tai K (2010) Australian & New Zealand Faculty of Radiation Oncology Genito-Urinary Group: 2010 consensus guidelines for definitive external beam radiotherapy for prostate carcinomaJournal of Medical Imaging and Radiation Oncology, 10.1111/j.1754-9485.2010.02214.x, VOL. 54, NO. 6, (513-525), Online publication date: 1-Dec-2010. Piña A, Crook J, Kwan P, Borg J and Ma C (2010) The impact of perineural invasion on biochemical outcome after permanent prostate iodine-125 brachytherapyBrachytherapy, 10.1016/j.brachy.2009.09.002, VOL. 9, NO. 3, (213-218), Online publication date: 1-Jul-2010. Roach M, Wallner K, Hsu I and Carroll P (2010) Cancer of the Prostate Leibel and Phillips Textbook of Radiation Oncology, 10.1016/B978-1-4160-5897-7.00046-9, (925-986), . Cheng L, Mazzucchelli R, Jones T, Lopez-Beltran A and Montironi R (2010) The Pathology of Prostate Cancer Early Diagnosis and Treatment of Cancer Series: Prostate Cancer, 10.1016/B978-1-4160-4575-5.50009-8, (45-83), . Liauw S, Fricano J, Correa D, Weichselbaum R and Jani A (2009) Dose-escalated radiation therapy for intermediate-risk prostate cancerCancer, 10.1002/cncr.24176, VOL. 115, NO. 8, (1784-1790), Online publication date: 15-Apr-2009. Kollmeier M and Zelefsky M (2008) Radiation therapy Prostate Cancer, 10.1017/CBO9780511551994.007, (58-92) Williams S, Buyyounouski M, Pickles T, Kestin L, Martinez A, Hanlon A and Duchesne G (2008) Percentage of Biopsy Cores Positive for Malignancy and Biochemical Failure Following Prostate Cancer Radiotherapy in 3,264 Men: Statistical Significance Without Predictive PerformanceInternational Journal of Radiation Oncology*Biology*Physics, 10.1016/j.ijrobp.2007.08.021, VOL. 70, NO. 4, (1169-1175), Online publication date: 1-Mar-2008. Eggener S, Scardino P, Carroll P, Zelefsky M, Sartor O, Hricak H, Wheeler T, Fine S, Trachtenberg J, Rubin M, Ohori M, Kuroiwa K, Rossignol M and Abenhaim L (2007) Focal Therapy for Localized Prostate Cancer: A Critical Appraisal of Rationale and ModalitiesJournal of Urology, VOL. 178, NO. 6, (2260-2267), Online publication date: 1-Dec-2007. Scattoni V, Zlotta A, Montironi R, Schulman C, Rigatti P and Montorsi F (2007) Extended and Saturation Prostatic Biopsy in the Diagnosis and Characterisation of Prostate Cancer: A Critical Analysis of the LiteratureEuropean Urology, 10.1016/j.eururo.2007.08.006, VOL. 52, NO. 5, (1309-1322), Online publication date: 1-Nov-2007. (2007) Appendices Clinical Pathology of Urological Tumours, 10.3109/9780203089835-26, (143-155), Online publication date: 24-Oct-2007. Spalding A, Daignault S, Sandler H, Shah R, Pan C and Ray M (2007) Percent Positive Biopsy Cores as a Prognostic Factor for Prostate Cancer Treated with External Beam RadiationUrology, 10.1016/j.urology.2007.01.066, VOL. 69, NO. 5, (936-940), Online publication date: 1-May-2007. Papagikos M, Rossi P, Urbanic J, deGuzman A, McCullough D, Clark P and Lee W (2007) A Simple Model Predicts Freedom From Biochemical Recurrence After Low-Dose Rate Prostate Brachytherapy AloneAmerican Journal of Clinical Oncology, 10.1097/01.coc.0000251402.85009.af, VOL. 30, NO. 2, (199-204), Online publication date: 1-Apr-2007. Roach M, Weinberg V, Sandler H and Thompson I (2007) Staging for prostate cancerCancer, 10.1002/cncr.22403, VOL. 109, NO. 2, (213-220), Online publication date: 15-Jan-2007. Frank S, Grimm P, Sylvester J, Merrick G, Davis B, Zietman A, Moran B, Beyer D, Roach M, Clarke D, Stock R, Robert Lee W, Michalski J, Wallner K, Hurwitz M, Potters L, Kuban D, Prestidge B, Vera R, Hathaway S and Blasko J (2007) Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer: A survey of practice patterns in the United StatesBrachytherapy, 10.1016/j.brachy.2006.09.004, VOL. 6, NO. 1, (2-8), Online publication date: 1-Jan-2007. Harnden P, Shelley M, Clements H, Coles B, Tyndale-Biscoe R, Naylor B and Mason M (2007) The prognostic significance of perineural invasion in prostatic cancer biopsiesCancer, 10.1002/cncr.22388, VOL. 109, NO. 1, (13-24), Online publication date: 1-Jan-2007. Hurwitz M, Schultz D, Richie J, Wein A, Whittington R, Malkowicz S and D’Amico A (2006) Radical prostatectomy for high-grade prostate cancerUrology, 10.1016/j.urology.2006.02.024, VOL. 68, NO. 2, (367-370), Online publication date: 1-Aug-2006. Montironi R, Vela Navarrete R, Lopez-Beltran A, Mazzucchelli R, Mikuz G and Bono A (2006) Histopathology reporting of prostate needle biopsies. 2005 updateVirchows Archiv, 10.1007/s00428-006-0190-9, VOL. 449, NO. 1, (1-13), Online publication date: 1-Jul-2006. Weight C, Ciezki J, Reddy C, Zhou M and Klein E (2006) Perineural invasion on prostate needle biopsy does not predict biochemical failure following brachytherapy for prostate cancerInternational Journal of Radiation Oncology*Biology*Physics, 10.1016/j.ijrobp.2005.12.054, VOL. 65, NO. 2, (347-350), Online publication date: 1-Jun-2006. MONTIRONI R, MAZZUCCHELLI R, SCARPELLI M, LOPEZ-BELTRAN A, MIKUZ G, ALGABA F and BOCCON-GIBOD L (2006) Prostate carcinoma II: prognostic factors in prostate needle biopsiesBJU International, 10.1111/j.1464-410X.2006.05973.x, VOL. 97, NO. 3, (492-497), Online publication date: 1-Mar-2006. Stock R, Cesaretti J and Stone N (2006) Disease-specific survival following the brachytherapy management of prostate cancerInternational Journal of Radiation Oncology*Biology*Physics, 10.1016/j.ijrobp.2005.09.005, VOL. 64, NO. 3, (810-816), Online publication date: 1-Mar-2006. Rossi P, Clark P, Papagikos M, McCullough D and Lee W (2006) Percentage of positive biopsies associated with freedom from biochemical recurrence after low-dose-rate prostate brachytherapy alone for clinically localized prostate cancerUrology, 10.1016/j.urology.2005.08.047, VOL. 67, NO. 2, (349-353), Online publication date: 1-Feb-2006. Algaba F, Arce Y, Oliver A, Barandica C, Santaularia J and Montañés R (2005) Prognostic Parameters Other Than Gleason Score for the Daily Evaluation of Prostate Cancer in Needle BiopsyEuropean Urology, 10.1016/j.eururo.2005.06.016, VOL. 48, NO. 4, (566-571), Online publication date: 1-Oct-2005. Copp H, Bissonette E and Theodorescu D (2005) Tumor control outcomes of patients treated with trimodality therapy for locally advanced prostate cancerUrology, 10.1016/j.urology.2004.12.014, VOL. 65, NO. 6, (1146-1151), Online publication date: 1-Jun-2005. Amin M, Boccon-Gibod L, Egevad L, Epstein J, Humphrey P, Mikuz G, Newling D, Nilsson S, Sakr W, Srigley J, Wheeler T and Montironi R (2009) Prognostic and predictive factors and reporting of prostate carcinoma in prostate needle biopsy specimensScandinavian Journal of Urology and Nephrology, 10.1080/03008880510030923, VOL. 39, NO. sup216, (20-33), Online publication date: 1-May-2005. Langley S and Laing R (2004) Iodine seed prostate brachytherapy: an alternative first-line choice for early prostate cancerProstate Cancer and Prostatic Diseases, 10.1038/sj.pcan.4500727, VOL. 7, NO. 3, (201-207), Online publication date: 1-Sep-2004. Wong W, Schild S, Vora S and Halyard M (2004) Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancerInternational Journal of Radiation Oncology*Biology*Physics, 10.1016/j.ijrobp.2004.02.031, VOL. 60, NO. 1, (24-29), Online publication date: 1-Sep-2004. Passavanti G, Pizzuti V, Costantini F, Bragaglia A, Minacci C, Stumpo M and Paolini R (2018) The Role of Histopathologic Grading in the Staging of Localized Prostate CancerUrologia Journal, 10.1177/039156030407100204, VOL. 71, NO. 2, (114-118), Online publication date: 1-Jan-2004. Khan M and Partin A (2003) Management of High-Risk Populations with Locally Advanced Prostate CancerThe Oncologist, 10.1634/theoncologist.8-3-259, VOL. 8, NO. 3, (259-269), Online publication date: 1-Jun-2003. Che M, Sakr W and Grignon D (2003) Pathologic features the urologist should expect on a prostate biopsyUrologic Oncology: Seminars and Original Investigations, 10.1016/S1078-1439(03)00008-5, VOL. 21, NO. 2, (153-161), Online publication date: 1-Mar-2003. Volume 168Issue 5November 2002Page: 1994-1999 Advertisement Copyright & Permissions© 2002 by American Urological Association, Inc.Keywordsbrachytherapyprostatic neoplasmsradiotherapyprostate-specific antigenbiopsyMetricsAuthor Information LARRY L. KESTIN Requests for reprints: Department of Radiation Oncology, William Beaumont Hospital, 3601 West Thirteen Mile Rd., Royal Oak, Michigan 48073. More articles by this author NEAL S. GOLDSTEIN More articles by this author FRANK A. VICINI More articles by this author ALVARO A. MARTINEZ More articles by this author Expand All Advertisement PDF downloadLoading ...